Core Viewpoint - The food and beverage ETF Tianhong (159736) has shown significant market activity, with a notable inflow of funds and rising stock prices among key components, indicating a positive trend in the sector [2][3]. Group 1: ETF Performance - The Tianhong food and beverage ETF (159736) experienced a slight decline of 0.28% as of the latest report, with a premium rate of 0.04% and frequent premium trading observed [1]. - The ETF has seen a net inflow of nearly 170 million yuan over the past nine trading days, with a total circulation of 7.62 billion shares, reaching a historical high [2]. Group 2: Component Stocks - Key component stocks such as Yangyuan Beverage, Gujing Gongjiu, Luzhou Laojiao, and others have shown price increases, with Yangyuan Beverage rising over 4% [2]. - The ETF closely tracks the CSI Food and Beverage Index, which includes major stocks from the beverage, packaged food, and meat industries, featuring top holdings like Kweichow Moutai, Yili, and Wuliangye [2]. Group 3: Market Trends - Reports indicate a significant increase in the prices of premium liquor, with notable price hikes for products like Feitian Moutai and other well-known brands over a short period [3]. - The liquor market is experiencing a surge in demand, particularly in the mid-range price segment (50-200 yuan), with increased sales reported across various regions [3]. - The upcoming National Day holiday is expected to boost tourism and consumer spending, with a projected 130% increase in travel compared to the previous year, indicating a potential for strong sales in the food and beverage sector [4].

Group 1 - The core point of the article is that Jindawei has received a patent for a coenzyme Q10 oil preparation method, which may enhance its product offerings and market position [1] - Jindawei's revenue composition for the first half of 2025 shows that industrial revenue accounts for 98.5%, pharmaceutical raw materials for 1.43%, and other businesses for 0.07% [1] - As of the report, Jindawei's market capitalization stands at 11.4 billion yuan [1]

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-085 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司厦门金达威生 物科技有限公司，近日收到国家知识产权局颁发的 1 件发明专利证书，具体情况 如下： 发明名称：一种辅酶 Q10 油剂及其制备方法和应用 专利号：ZL 2023 1 0111297.8 专利申请日：2023 年 02 月 14 日 专利权人：厦门金达威生物科技有限公司 厦门金达威集团股份有限公司 专利权期限：二十年 证书号：第 8302360 号 授权公告日：2025 年 09 月 26 日 本发明属于辅酶 Q10 技术领域，涉及一种辅酶 Q10 油剂及其制备方法和应 用。本发明提供的辅酶 Q10 油剂中辅酶 Q10 在高含量下仍然能够稳定地以分子 形态存在，生物利用度高。 上述专利的取得不会对公司生产经营产生重大影响，但有利于公司的技术 ...

Core Viewpoint - The company, Jin Da Wei, and its subsidiary, Xiamen Jin Da Wei Biotechnology Co., Ltd., have received an invention patent certificate from the National Intellectual Property Administration for a coenzyme Q10 oil preparation and its manufacturing method, which enhances the company's technological innovation and strengthens its core competitiveness [1] Group 1 - The patent is beneficial for the company's technological innovation [1] - The patent contributes to the improvement of the intellectual property protection system [1] - The patent enhances the company's core competitiveness [1]

近日，厦门金达威集团股份有限公司及子公司厦门金达威生物科技有限公司收到国家知识产权局颁发的 发明专利证书。发明名称为"一种辅酶Q10油剂及其制备方法和应用"，专利号ZL202310111297.8，申请 日为2023年，专利权期限二十年，授权公告日为2025年。该发明涉及辅酶Q10技术领域，其辅酶Q10油 剂中辅酶Q10高含量下能稳定以分子形态存在、生物利用度高。此专利取得虽不对公司生产经营产生重 大影响，但利于技术创新、完善知识产权保护体系及增强核心竞争力。 ...

Core Insights - The food processing sector experienced a slight decline of 0.16% on September 24, with Weizhi Xiang leading the drop [1][2] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Stock Performance - Notable gainers in the food processing sector included: - Baba Foods (605338) with a closing price of 23.57, up 4.90% [1] - Guangming Meat (600073) at 7.05, up 2.47% [1] - ST Chuntian (600381) at 5.19, up 2.37% [1] - Conversely, Weizhi Xiang (605089) closed at 28.11, down 1.54% [2] - The sector saw a total trading volume of 5.67 billion yuan in net outflow from major funds, while retail investors contributed a net inflow of 2.49 billion yuan [2][3] Fund Flow Analysis - Major funds showed a net outflow of 5.67 billion yuan, while speculative funds had a net inflow of 3.18 billion yuan [2] - Retail investors contributed a net inflow of 2.49 billion yuan [2] - Specific stock fund flows included: - Guangming Meat (600073) with a net inflow of 17.05 million yuan from major funds [3] - Jindawi (002626) with a net inflow of 11.20 million yuan from major funds [3] - Xianle Health (300791) had a net inflow of 2.03 million yuan from retail investors [3]

Core Viewpoint - The company, Jindawei, has advanced production technology and scale, holding multiple invention patents, including reduced coenzyme Q10, in China and the United States [1] Group 1: Company Overview - Jindawei has a leading position in production technology and scale [1] - The company possesses several invention patents related to reduced coenzyme Q10 [1] Group 2: Market Analysis - The sales proportion of reduced coenzyme Q10 in the market is currently low [1] - The company has conducted research and analysis on the market prospects for reduced coenzyme Q10 [1]

Core Viewpoint - The stock of Kingdawei has experienced fluctuations, with a recent decline of 2.04% on September 18, 2023, while the company has shown a year-to-date increase of 30.61% in stock price [1] Financial Performance - For the first half of 2025, Kingdawei reported a revenue of 1.728 billion yuan, representing a year-on-year growth of 13.46%, and a net profit attributable to shareholders of 247 million yuan, which is a significant increase of 90.12% [2] - Cumulatively, since its A-share listing, Kingdawei has distributed a total of 2.761 billion yuan in dividends, with 488 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Kingdawei is 40,700, a decrease of 4.30% from the previous period, while the average circulating shares per person increased by 4.50% to 14,976 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.5915 million shares, and Southern CSI 1000 ETF, which increased its holdings by 521,500 shares [3] Market Activity - On September 18, 2023, Kingdawei's stock price was 19.20 yuan per share, with a trading volume of 145 million yuan and a turnover rate of 1.22%, resulting in a total market capitalization of 11.711 billion yuan [1] - The net outflow of main funds was 11.648 million yuan, with significant selling pressure observed in large orders [1] Business Overview - Kingdawei, established on November 24, 1997, and listed on October 28, 2011, is primarily engaged in the manufacturing of health food and nutritional products, with its main revenue sources being health food (54.57%), coenzyme Q10 series (22.04%), and vitamin A series (11.41%) [1] - The company is classified under the food and beverage industry, specifically in food processing and health products [1]

Core Viewpoint - The company, Jindawei, reported that its revenue in the United States is primarily derived from two sources: income from its U.S. subsidiary and exports from its domestic subsidiary, mainly focusing on coenzyme Q10. The company stated that the U.S.-China trade relationship does not significantly impact its operations [1] Group 1 - The U.S. subsidiary's income is largely unaffected by U.S.-China trade tensions [1] - Exports to the U.S. mainly consist of coenzyme Q10, with the majority of raw materials sourced from China [1] - The U.S. is the largest consumer market for coenzyme Q10 globally, indicating strong demand [1] Group 2 - The company's exports to the U.S. are influenced by downstream customer inventory cycles and market supply-demand changes [1] - Currently, the impact of U.S.-China trade relations on the company's operations is minimal [1]

Group 1: Company Operations and Market Position - The company is the largest producer of Coenzyme Q10 globally, recognized for its quality and production capacity, which is at the industry's leading level [2][3] - The company has undergone capacity expansion and transformation, significantly reducing production costs and increasing market share, thereby reinforcing its dominant market position [3] - Coenzyme Q10 is widely used in cardiovascular health and anti-aging sectors, with market demand expected to continue growing due to global aging and rising health awareness [3] Group 2: Product Development and Market Strategy - The company plans to closely monitor developments in the health and biosynthesis sectors, aligning R&D projects with market prospects and enhancing its synthetic biology research platform [2] - The company aims to strengthen its raw material supply chain and accelerate the industrialization of new products, focusing on biosynthesis research and global brand strategy [3] - The company is committed to building a strong brand presence in the health supplement market through a "big product + product matrix" strategy, leveraging both raw material and brand advantages [3] Group 3: Competitive Landscape - The U.S. dietary supplement market is highly fragmented, with the company focusing on maintaining its operational philosophy and differentiation to enhance market share for its star products [3] - The Doctor's Best brand emphasizes the use of high-quality raw materials and targets consumers interested in scientifically formulated nutrition, maintaining a leading position in the market [3]